ATE197719T1 - Verwendung von mesothelialen zellen in der gentherapie - Google Patents

Verwendung von mesothelialen zellen in der gentherapie

Info

Publication number
ATE197719T1
ATE197719T1 AT94920753T AT94920753T ATE197719T1 AT E197719 T1 ATE197719 T1 AT E197719T1 AT 94920753 T AT94920753 T AT 94920753T AT 94920753 T AT94920753 T AT 94920753T AT E197719 T1 ATE197719 T1 AT E197719T1
Authority
AT
Austria
Prior art keywords
mesothelial cells
mesothelial
expression system
gene therapy
situ
Prior art date
Application number
AT94920753T
Other languages
English (en)
Inventor
Ty Robert Shockley
Robert William Jackman
Janice Ann Nagy
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE197719T1 publication Critical patent/ATE197719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94920753T 1993-06-18 1994-06-15 Verwendung von mesothelialen zellen in der gentherapie ATE197719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/080,474 US5645829A (en) 1993-06-18 1993-06-18 Mesothelial cell gene therapy
PCT/US1994/006809 WO1995000654A1 (en) 1993-06-18 1994-06-15 Mesothelial cell gene therapy

Publications (1)

Publication Number Publication Date
ATE197719T1 true ATE197719T1 (de) 2000-12-15

Family

ID=22157605

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920753T ATE197719T1 (de) 1993-06-18 1994-06-15 Verwendung von mesothelialen zellen in der gentherapie

Country Status (9)

Country Link
US (2) US5645829A (de)
EP (2) EP1024197A3 (de)
JP (1) JP3466194B2 (de)
AT (1) ATE197719T1 (de)
AU (1) AU688342B2 (de)
CA (1) CA2164424A1 (de)
DE (1) DE69426328T2 (de)
ES (1) ES2152986T3 (de)
WO (1) WO1995000654A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1996006933A1 (en) * 1994-08-26 1996-03-07 Sandoz Ltd. Gene therapy for transplantation and inflammatory or thrombotic conditions
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
DE69839765D1 (de) 1997-01-27 2008-09-04 Ludwig Inst Cancer Res Lage-1 tumor-assozierte nukleinsäuren
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
WO1999008533A1 (en) * 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
EP2006300A3 (de) 1998-12-30 2009-03-11 Beth Israel Deaconess Medical Center, Inc. Charakterisierung einer Calciumkanalfamilie
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6696272B1 (en) 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
DE60044904D1 (de) 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
DK1515752T3 (da) 2002-06-19 2009-03-23 Univ Health Network ACE2-aktivering til behandling af hjerte-, lunge- og nyresygdomme og hypertension
SI2325302T1 (sl) 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
US20060052324A1 (en) * 2004-08-05 2006-03-09 Artandi Steven E Methods and compositions for cell activation
DE602005022481D1 (de) * 2004-12-08 2010-09-02 Pervasis Therapeutics Inc Zusammensetzungen und deren verwendung für besseren gefässzugang
JP5174656B2 (ja) 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー 同系または非同系の細胞、組織または器官を含む、外因性免疫原および内因性免疫原に対する免疫応答を改変するための材料および方法
US20090035346A1 (en) * 2005-06-21 2009-02-05 Pervasis Therpeutics, Inc. Methods and Compositions for Enhancing Vascular Access
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CA2642848C (en) 2006-03-03 2016-07-12 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
CA2668621A1 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
EP2377952A1 (de) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
EP2113261B1 (de) * 2008-04-29 2013-11-06 Proxy Biomedical Limited Gewebereparaturimplantat
WO2010071692A2 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
WO2011076095A1 (en) 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
EP2920319B1 (de) 2012-11-16 2020-02-19 Poseida Therapeutics, Inc. Ortsspezifische enzyme und verfahren zur verwendung
CA2928411A1 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use
RU2553342C1 (ru) * 2014-04-18 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения инфекционного перитонита в эксперименте
EP3929286A1 (de) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur führung von proteinen an spezifische loci im genom
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755593A (en) * 1985-07-24 1988-07-05 Lauren Mark D Novel biomaterial of cross-linked peritoneal tissue
US5443954A (en) * 1987-10-30 1995-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immortalized non-tumorigenic human bronchial epithelial cell lines
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
EP0456640A1 (de) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU625013B2 (en) * 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DE4011100A1 (de) * 1990-01-18 1991-10-10 Jakob Dr Bodziony Ein extrakorporales oder ein implantierbares bio-artifizielles organ, welches verschiedene organfunktionen ersetzen oder unterstuetzen kann
DE4001319A1 (de) * 1990-01-18 1991-07-25 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bioartifizielles organ
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
DE4123629A1 (de) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bio-artifizielles organ, das auf dem prinzip des druckgradients funktioniert
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
EP0563239A4 (de) * 1990-12-20 1994-10-12 Univ Pittsburgh Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis.
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
AU663725B2 (en) * 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
JP3466194B2 (ja) 2003-11-10
DE69426328D1 (de) 2000-12-28
AU7174194A (en) 1995-01-17
ES2152986T3 (es) 2001-02-16
AU688342B2 (en) 1998-03-12
EP0703988B1 (de) 2000-11-22
US6068837A (en) 2000-05-30
EP0703988A1 (de) 1996-04-03
CA2164424A1 (en) 1995-01-05
EP1024197A3 (de) 2005-11-23
JPH09501048A (ja) 1997-02-04
DE69426328T2 (de) 2002-05-29
EP1024197A2 (de) 2000-08-02
US5645829A (en) 1997-07-08
WO1995000654A1 (en) 1995-01-05

Similar Documents

Publication Publication Date Title
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
ATE420156T1 (de) Methode zur einführung von genetischem material in zellen
EP0939590A4 (de) Verabreichung therapeutischer genprodukte durch intestinale zell-expression
CY1119369T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ATE370749T1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
FI914427A0 (fi) Expression av exogena polynukleotid- sekvenser i ett ryggradsdjur.
ATE157012T1 (de) Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
DK0661987T3 (da) Morphogeninduceret leverregeneration
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
BR9806866A (pt) Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.
FR2730411B1 (fr) Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
AU2520595A (en) Virosome-mediated intracellular delivery of therapeutic agents
DE69909041D1 (de) Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
ES2080954T3 (es) Uso de beta-aletina en cultivos de celulas y en terapia.
ATE286127T1 (de) Verabreichung der therapeutischen proteine durch implantation der genetischen modifizierten zellen in das omentum
FR2622445B1 (fr) Application de groupes nitrophenyles a la stimulation des capacites d'incorporation d'un medicament dans les cellules sensibles de l'hote
IL148826A (en) Genetically modified mammalian cells and use thereof for the pulmonary system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties